THURSDAY, JANUARY 23, 2003

3:30 pm – 5:30 pm  Sign-in at Tradewinds Conference Room

7:00 pm – 9:00 pm  Reception

FRIDAY, JANUARY 24, 2003

7:00 am – 8:00 am  Continental Breakfast

8:00 am – 9:00 am  Welcome address:  Review of NAPRTCS Accomplishments of the Past Decade:  William Harmon, MD, President, NAPRTCS

9:00 am – 10:00 am  NAPRTCS reorganization plan:  Steven Alexander, MD, Secretary, NAPRTCS

10:00 am – 10:45 am  Break

10:45 am – 11:30 am  Role of NIH in NAPRTCS Studies:  Shiv Prasad, NIAID

How HIPAA Regulations Will Affect NAPRTCS:
William Harmon, MD, President, NAPRTCS

New Web-based Data Entry System:  Donald Stablein, Ph. D., EMMES

11:30 am – 1:00 pm  Lunch (hands-on tutorials in web-based data entry will be available)
1:00 pm – 3:15 pm  Break-out session for data coordinators and study nurses

1:00 pm – 1:45 pm  Embryonic Stem Cells and the Origin of Regenerative Medicine:
Terry Strom, MD, Ph.D., Beth Israel Deaconess Medical Center

1:45 pm - 2:30 pm  Measuring Alloreactivity: What Have We Learned:  Mo Sayegh,
MD  Brigham and Women’s Hospital

2:30 pm – 3:15 pm  Noninvasive Diagnosis of Renal Allograft Rejection:  Manikkam
Suthanthiran, MD, Cornell University Medical Center

3:15 pm – 3:45 pm  Break

3:45 pm – 4:30 pm  NAPRTCS Transplant, Dialysis and CRI Registry Updates: Mark
Benfield, MD,

4:30 pm  Adjourn

Dinner on your own ($50 NAPRTCS expense allowance)

SATURDAY, JANUARY 25, 2003

7:00 am – 8:00 am  Continental Breakfast

8:00 am – 8:45 am  (CRI) Title TBA:  Speaker TBA

8:45 am - 9:30 am  (Dialysis) Title TBA:  Speaker TBA

9:30 am - 10:15 am  (Dialysis) Title TBA:  Speaker TBA

10:15 am – 10:45 am  Break

10:45 am – 11:15 am  Current NAPRTCS Studies:

Steroid Withdrawal (NIH):  William Harmon, MD

Calcineurin Inhibitor Avoidance (NIH):  William Harmon, MD

TGF? 1 and Excess Renal Disease in African Americans (NIH):
Richard Fine, MD
“Open Label Multicenter Study of the Safety and Efficacy of Ferreliciit in the Maintenance of Iron Stores in Pediatric Hemodialysis Patients Receiving Epoetin” (Watson Laboratories): Bradley Warady, MD

“A Randomized, Double Blind Parallel Group Multicenter Study of the Efficacy of Two Doses of Ferreliciit in the Treatment of Iron Deficiency in Pediatric Dialysis Patients Receiving Epoetin” (Watson Laboratories): Bradley Warady, MD

11:15 am – 12:30 pm  Upcoming NAPRTCS Studies (funded* and proposed**)

11:15 am – 11:40 am  **U01 Update (NIH) “New NAPRTCS Trials in Steroid-free Immunosuppression” Oscar Salvatierra, MD; Minnie Sarwal, MD, PhD; Steven Alexander, MD

11:40 am – 11:55 am  **CTLA4 Ig Application Update (NIH): William Harmon, MD; Mo Sayegh, MD, PhD

11:55 am – 12:05 pm  ** “IVIG For Sensitized Living Donor Kidney Transplant Candidates” (NIH): William Harmon, MD

12:05 pm – 12:20 pm  ** “Optimal Treatment of FSGS” (NIH): Richard Fine, MD

12:20 pm – 12:30 pm  **Aranesp Study (Amgen): Bradley Warady, MD

12:30pm – 1:00pm  Completed NAPRTCS Studies:

Induction Antibody (NIH): William Harmon, MD

Chronic Rejection Study (NIH): William Harmon, MD

Growth Hormone Post-Transplant: Richard Fine, MD

Growth Hormone in Dialysis: Bradley Warady, MD

1:00 pm – 2:00 pm  Adjourn and Luncheon